Sound Medicine – Avastin’s Benefits Overstated for Breast Cancer

Sound Medicine is a radio show produced by the Indiana University School of Medicine and WFYI Public Radio. In the last few years, I’ve become their go-to guy on health policy. So, for those of you who would find your day brightened by the sound of my voice, enjoy the following.

Indiana University health care policy expert Aaron Carroll, MD, weighs in on the debate over FDA approval of Avastin for late-stage cancer patients.

He views the drug as minimally effective, a cause of serious side effects, and too expensive to warrant its use for late-stage breast cancer patients.

Audio after the jump.

Aaron Carroll

Aaron E. Carroll, MD, MS is co-Editor-in-Chief of The Incidental Economist and tweets at @aaronecarroll. He is the Chief Health Officer at Indiana University. He is also a Distinguished Professor of Pediatrics and Associate Dean for Research Mentoring at the Indiana University School of Medicine. In addition to contributing regularly to The New York Times and the Atlantic, he is the author of four books, most recently The Bad Food Bible.

Hidden information below

Aaron Carroll

Aaron E. Carroll, MD, MS is co-Editor-in-Chief of The Incidental Economist and tweets at @aaronecarroll. He is the Chief Health Officer at Indiana University. He is also a Distinguished Professor of Pediatrics and Associate Dean for Research Mentoring at the Indiana University School of Medicine. In addition to contributing regularly to The New York Times and the Atlantic, he is the author of four books, most recently The Bad Food Bible.

The Incidental Economist

the health services research blog

Boston-area website management by BKJ Productions
Editors In Chief
Managing Editor

Work posted here under copyright © of the authors • Details on the Site Policies page

Subscribe

Email Address*